STOK

Stoke Therapeutics, Inc. NASDAQ Listed Jun 19, 2019

Healthcare ·Biotechnology ·US · stoketherapeutics.com

$32.85

After hrs $31.07 -5.23%

Mkt Cap $1.9B

52w Low $8.51 76.8% of range 52w High $40.22

50d MA $34.38 200d MA $28.55

P/E (TTM) -275.7x

EV/EBITDA -95.4x

P/B 5.6x

Debt/Equity 0.0x

ROE -1.9%

P/FCF 41.8x

RSI (14) —

ATR (14) —

Beta 1.22

50d MA $34.38

200d MA $28.55

Avg Volume 740.0K

About

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in ph…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-0.75	-0.97	-29.3%	33.96	-3.2%	-3.2%	-8.7%	-2.3%	-1.3%	-1.6%	—
Nov 4, 2025	AMC	-0.54	-0.65	-20.4%	25.34	-13.4%	-9.9%	-11.3%	-9.8%	-11.7%	-0.9%	—
Aug 12, 2025	AMC	-0.57	-0.40	+29.8%	13.53	+10.1%	+25.0%	+26.9%	+34.6%	+36.8%	+36.7%	—
May 13, 2025	AMC	-0.37	1.90	+613.5%	8.93	-2.5%	+0.7%	+7.8%	+9.3%	+10.1%	+12.5%	—
Mar 18, 2025	AMC	-0.51	-0.18	+64.7%	8.87	+0.9%	-6.9%	-6.1%	-8.1%	-6.5%	-12.7%	—
Nov 5, 2024	AMC	-0.52	-0.47	+9.6%	13.05	+5.0%	+1.5%	+1.7%	+6.4%	+5.8%	+4.4%	—
Aug 7, 2024	AMC	-0.57	-0.46	+19.3%	13.71	+3.9%	+3.1%	+5.2%	+5.4%	+3.4%	+1.9%	—
May 6, 2024	AMC	-0.60	-0.57	+5.0%	11.87	+0.1%	+0.6%	-2.3%	+1.2%	-3.3%	-2.7%	—
Mar 25, 2024	AMC	-0.62	-0.60	+3.2%	6.50	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%	—
Nov 7, 2023	AMC	-0.65	-0.55	+15.4%	4.85	+0.0%	-4.9%	-6.6%	-12.2%	-12.0%	-2.9%	—
Aug 7, 2023	AMC	-0.65	-0.69	-6.2%	5.85	-2.1%	-5.1%	-4.6%	-2.9%	-7.0%	-6.7%	—
May 4, 2023	AMC	-0.70	-0.53	+24.3%	10.72	+0.5%	+11.5%	+12.3%	+13.4%	+8.7%	+7.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	Canaccord Genuity	Maintains	Buy → Buy	—	$33.19	$34.10	+2.7%	+1.0%	+0.6%	-3.0%	+1.8%	+1.5%
Mar 19	BTIG	Maintains	Buy → Buy	—	$31.02	$29.99	-3.3%	+7.0%	+8.0%	+7.7%	+3.7%	+8.9%
Mar 18	Wedbush	Maintains	Outperform → Outperform	—	$32.87	$32.85	-0.1%	-5.6%	+1.0%	+1.9%	+1.6%	-2.1%
Mar 18	Chardan Capital	Maintains	Buy → Buy	—	$32.87	$32.85	-0.1%	-5.6%	+1.0%	+1.9%	+1.6%	-2.1%
Mar 17	Wedbush	Maintains	Outperform → Outperform	—	$33.96	$32.89	-3.2%	-3.2%	-8.7%	-2.3%	-1.3%	-1.6%
Mar 17	Needham	Maintains	Buy → Buy	—	$33.96	$32.89	-3.2%	-3.2%	-8.7%	-2.3%	-1.3%	-1.6%
Jan 12	Wedbush	Maintains	Outperform → Outperform	—	$32.85	$27.40	-16.6%	-10.4%	-6.9%	-5.7%	-10.9%	-12.6%
Jan 5	Chardan Capital	Maintains	Buy → Buy	—	$30.90	$30.71	-0.6%	+5.3%	+14.0%	+13.8%	+9.0%	+6.3%
Jan 5	Canaccord Genuity	Maintains	Buy → Buy	—	$30.90	$30.71	-0.6%	+5.3%	+14.0%	+13.8%	+9.0%	+6.3%
Dec 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.39	$33.13	+2.3%	+1.8%	+3.8%	+1.5%	-1.4%	-1.3%
Nov 5	Canaccord Genuity	Maintains	Buy → Buy	—	$25.34	$21.94	-13.4%	-9.9%	-11.3%	-9.8%	-11.7%	-0.9%
Nov 5	Wedbush	Maintains	Outperform → Outperform	—	$25.34	$21.94	-13.4%	-9.9%	-11.3%	-9.8%	-11.7%	-0.9%
Nov 5	BTIG	Maintains	Buy → Buy	—	$25.34	$21.94	-13.4%	-9.9%	-11.3%	-9.8%	-11.7%	-0.9%
Nov 3	JP Morgan	Maintains	Neutral → Neutral	—	$30.04	$29.30	-2.5%	-13.1%	-15.6%	-24.0%	-25.2%	-23.9%
Oct 13	BTIG	Maintains	Buy → Buy	—	$30.19	$30.18	-0.0%	+0.5%	+15.7%	+17.9%	+13.2%	+11.1%
Oct 10	Needham	Maintains	Buy → Buy	—	$29.90	$30.95	+3.5%	+1.0%	+1.5%	+16.9%	+19.1%	+14.3%
Aug 13	Wedbush	Maintains	Outperform → Outperform	—	$13.53	$14.89	+10.1%	+25.0%	+26.9%	+34.6%	+36.8%	+36.7%
Aug 13	Chardan Capital	Maintains	Buy → Buy	—	$13.53	$14.89	+10.1%	+25.0%	+26.9%	+34.6%	+36.8%	+36.7%
Jul 1	Needham	Maintains	Buy → Buy	—	$11.35	$11.25	-0.9%	+2.6%	+1.8%	+1.1%	+3.0%	+5.8%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.93	$8.71	-2.5%	+0.7%	+7.8%	+9.3%	+10.1%	+12.5%
Apr 9	Needham	Maintains	Buy → Buy	—	$5.90	$5.76	-2.4%	+9.0%	+10.5%	+19.0%	+28.1%	+31.4%
Mar 19	Chardan Capital	Maintains	Buy → Buy	—	$8.87	$8.95	+0.9%	-6.9%	-6.1%	-8.1%	-6.5%	-12.7%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.87	$8.95	+0.9%	-6.9%	-6.1%	-8.1%	-6.5%	-12.7%
Mar 18	Needham	Maintains	Buy → Buy	—	$9.00	$8.63	-4.1%	-1.4%	-8.2%	-7.4%	-9.4%	-7.9%
Feb 19	Chardan Capital	Maintains	Buy → Buy	—	$9.71	$9.80	+0.9%	-4.2%	-10.0%	-14.2%	-12.5%	-15.0%
Feb 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.68	$10.80	+1.1%	-9.1%	-12.9%	-18.2%	-22.0%	-20.4%
Feb 18	Needham	Maintains	Buy → Buy	—	$10.68	$10.80	+1.1%	-9.1%	-12.9%	-18.2%	-22.0%	-20.4%
Jan 8	Needham	Maintains	Buy → Buy	—	$9.31	$9.54	+2.5%	-3.8%	-3.3%	-4.2%	-6.8%	+1.9%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.31	$9.54	+2.5%	-3.8%	-3.3%	-4.2%	-6.8%	+1.9%
Dec 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.76	$13.89	+0.9%	-3.6%	-5.7%	-10.5%	-12.4%	-11.0%
Nov 6	Needham	Maintains	Buy → Buy	—	$13.05	$13.70	+5.0%	+1.5%	+1.7%	+6.4%	+5.8%	+4.4%
Nov 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.05	$13.70	+5.0%	+1.5%	+1.7%	+6.4%	+5.8%	+4.4%
Sep 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.92	$15.84	-0.5%	-7.4%	-13.9%	-9.1%	-7.5%	-5.0%
Aug 8	Needham	Maintains	Buy → Buy	—	$13.71	$14.24	+3.9%	+3.1%	+5.2%	+5.4%	+3.4%	+1.9%
Jul 11	Wedbush	Maintains	Outperform → Outperform	—	$13.26	$13.71	+3.4%	+5.8%	+7.5%	+10.0%	+11.2%	+3.2%
Jun 28	Needham	Maintains	Buy → Buy	—	$13.31	$13.60	+2.2%	+1.5%	+4.2%	-3.6%	-4.8%	-1.4%
May 7	Canaccord Genuity	Maintains	Buy → Buy	—	$11.87	$11.88	+0.1%	+0.6%	-2.3%	+1.2%	-3.3%	-2.7%
May 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.87	$11.88	+0.1%	+0.6%	-2.3%	+1.2%	-3.3%	-2.7%
May 6	Needham	Maintains	Buy → Buy	—	$12.02	$12.02	+0.0%	-1.2%	-0.7%	-3.5%	-0.1%	-4.5%
Apr 11	Needham	Maintains	Buy → Buy	—	$12.76	$12.88	+0.9%	+5.8%	+0.1%	-4.3%	-2.4%	-8.2%
Mar 26	JP Morgan	Maintains	Neutral → Neutral	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Mar 26	Needham	Maintains	Buy → Buy	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Mar 26	Wedbush	Maintains	Outperform → Outperform	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Mar 26	Canaccord Genuity	Maintains	Buy → Buy	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Mar 26	TD Cowen	Upgrade	Hold → Buy	—	$6.50	$11.07	+70.3%	+58.3%	+118.0%	+107.7%	+107.5%	+101.2%
Feb 16	Needham	Maintains	Buy → Buy	—	$5.31	$5.24	-1.3%	-0.8%	+1.3%	+0.9%	+0.2%	+11.9%
Nov 7	Needham	Maintains	Buy → Buy	—	$4.31	$4.31	+0.0%	+12.5%	+7.0%	+5.1%	-1.2%	-0.9%
Aug 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.85	$5.73	-2.1%	-5.1%	-4.6%	-2.9%	-7.0%	-6.7%
Aug 8	Credit Suisse	Maintains	Outperform → Outperform	—	$5.85	$5.73	-2.1%	-5.1%	-4.6%	-2.9%	-7.0%	-6.7%

Insider Trades

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
May 1, 2026	Ticho Barry	CHIEF MEDICAL OFFICER	Sell	2,243	$32.79	$74K	36,621	+0.97%	—

Recent Filings

8-K

Unknown — 8-K Filing

Kahn's board appointment under standard compensation terms poses minimal risk, but investors should monitor whether new director expertise meaningfully strengthens governance or strategic oversight capabilities.

Apr 7

8-K · 4.01 !!! Very High

Unknown — 8-K 4.01: Auditor Change / Resignation

Stoke's auditor resignation raises red flags about potential accounting disagreements, which could indicate undisclosed financial issues and warrants immediate investor scrutiny of the company's disclosures.

Mar 27

8-K

Stoke Therapeutics, Inc. -- 8-K Filing

I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical SEC schema metadata rather than substantive business information about Stoke Therapeutics.

Mar 3

Data updated apr 27, 2026 3:18am · Source: massive.com